Psych Vivas · Addiction psychiatry
Alcohol use disorder — structured clinical viva
Fellowship viva on delirium tremens, CIWA-Ar, thiamine/Caine, naltrexone opioid trap, acamprosate/disulfiram doses, dual diagnosis pointer.
On this page & tools
Target exams
Interpretation
Reveal interpretation
Diagnosis. Delirium tremens — ~50 hours after last drink, fluctuating consciousness, severe autonomic hyperactivity, formed hallucinations. This is a medical emergency, not a primary behavioural disturbance.[1]
Differential. Other delirium (infection, metabolic, head injury from trauma), Wernicke encephalopathy (may coexist), alcohol hallucinosis without full delirium, benzo withdrawal if co-dependent, hepatic encephalopathy if cirrhotic.[1][3][6]
Immediate management. Continuous monitoring; CIWA-Ar if usable but do not withhold treatment if unassessable; high-dose benzodiazepines titrated to control agitation/autonomics (agent choice: diazepam or lorazepam if liver disease — name local protocol); parenteral thiamine high-dose if Wernicke risk; electrolytes (Mg/K/phosphate); medical/ICU escalation if refractory. Antipsychotics are not first-line for DT physiology.[1][2][6]
Naltrexone tonight. No while on oxycodone — precipitated opioid withdrawal and blocked analgesia. After opioid-free interval and consent, oral naltrexone 50 mg daily (or XR-NTX later) is reasonable; alternatives acamprosate 666 mg TDS or supervised disulfiram. Pair with psychosocial care; cite COMBINE nuances if asked.[4][5]
Escalating viva probes
| Probe | Model point |
|---|---|
| CIWA-Ar structure | Ten items, max 67; symptom-triggered benzos |
| Caine criteria | Any 2 of 4 → treat as Wernicke |
| Seizure window | Roughly 12–48 h after last drink |
| Acamprosate dose | 666 mg TDS; renal adjust |
| COMBINE pearl | Naltrexone/medical management effects; acamprosate null in that design |
Key points
[1] [3] [4]References
- [1]Mayo-Smith MF Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA, 1997.PMID 9214531
- [2]Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict, 1989.PMID 2597811
- [3]Caine D, Halliday GM, Kril JJ, et al. Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry, 1997.PMID 9010400
- [4]Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry, 2018.PMID 29301420
- [5]Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA, 2006.PMID 16670409
- [6]Galvin R, Bråthen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol, 2010.PMID 20642790